Crossmark

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Crossref DOI link: https://doi.org/10.1186/s12935-024-03319-z

Published Online: 2024-04-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Muller, Claire

Lacroix-Malgras, Victorine

Kluza, Jérôme

Laine, William

Güler, Yonca

Bost, Frédéric

Boisbrun, Michel

Mazerbourg, Sabine

Flament, Stéphane
Funding

Funding for this research was provided by:

French Ministère de l'Enseignement Supérieur et de la Recherche

Ligue Contre le Cancer
License Information

Text and Data Mining valid from 2024-04-10

Version of Record valid from 2024-04-10
More Information

Article History

Received: 7 November 2023

Accepted: 30 March 2024

First Online: 10 April 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below